Many cancers harbor pro-proliferative mutations of the mitogen-activated protein kinase (MAPK) pathway. In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape ...

A new research paper was published in Oncotarget's Volume 14 on May 26, 2023, entitled, "Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide ...

When the MAPK pathway has an abnormality, it can lead to the proliferation of cancer cells. “Extending our research into the combination setting in adult and adolescent patients is a logical next step ...

Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Quiver AI Summary Erasca, Inc. presented new preclinical data at the ...

The first patient was enrolled in a phase 1b trial evaluating the combination of the ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in patients with RAS/MAPK pathway-driven cancers, according ...

Pasithea Therapeutics announces rapid enrollment of three subjects in Phase 1 trial for PAS-004 targeting MAPK pathway cancers. Quiver AI Summary Pasithea Therapeutics Corp. has announced the ...